Monsanto Drops Bid for Syngenta

Monsanto has abandoned plans to acquire Syngenta, a merger which would have created an agricultural giant, after the Swiss seeds company rejected its latest bid of Swiss Francs 470 per share.

In a statement, Monsanto said while it continued to believe a combination with Syngenta would have created tremendous value for shareowners of both companies and farmers, the enhanced proposal did not meet Syngenta’s financial expectations.

“Without a basis for constructive engagement from Syngenta, Monsanto will continue to focus on its growth opportunities built on its existing core business to deliver the next wave of transformational solutions for agriculture,” Monsanto said.

Syngenta confirmed it had rejected the sweetened offer because it significantly undervalued the company and was fraught with execution risk. The company added that Monsanto did not provide sufficient detail on certain key issues which would have allowed Syngenta to properly asses the new entity, which would have been 30% owned by Syngenta shareholders.

The issues which Syngenta said lacked clarity were: an estimate of total cost and revenue synergies; assumptions regarding net sales proceeds of seeds and traits; the nature and extent of regulatory covenants that Monsanto was prepared to offer; the assessment of risks and benefits from a tax inversion to the UK.

Michel Demaré, chairman of Syngenta, said: “We engaged with Monsanto in good faith and highlighted those key issues which required more concrete information in order to continue a dialogue. Our board is confident that Syngenta’s long-term prospects remain very attractive with a leading portfolio and a promising pipeline of new products and technologies. We are committed to accelerate shareholder value creation.”

Monsanto said it will now focus on more than doubling fiscal 2014 earnings by 2019 and will resume its share repurchase program “as soon as practical”.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.